Ventyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. Wainwright
PremiumThe FlyVentyx’s Phase 2 programs ‘high risk/high reward,’ says H.C. Wainwright
3M ago
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates
Premium
Company Announcements
Ventyx Biosciences Unveils 2025 Pipeline and Clinical Updates
3M ago
Ventyx Biosciences highlights its 2025 pipeline strategy
Premium
The Fly
Ventyx Biosciences highlights its 2025 pipeline strategy
3M ago
Sanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright
PremiumThe FlySanofi investment in Ventyx shows VTX3232 interest, says H.C. Wainwright
6M ago
Ventyx Biosciences announces $27M investment from Sanofi
Premium
The Fly
Ventyx Biosciences announces $27M investment from Sanofi
6M ago
Ventyx Biosciences announces first patient dosed in Phase 2a trial of VTX3232
Premium
The Fly
Ventyx Biosciences announces first patient dosed in Phase 2a trial of VTX3232
7M ago
VTYX Earnings this Week: How Will it Perform?
PremiumPre-EarningsVTYX Earnings this Week: How Will it Perform?
8M ago
Ventyx Biosciences reports Q2 EPS (45c), consensus (58c)
Premium
The Fly
Ventyx Biosciences reports Q2 EPS (45c), consensus (58c)
8M ago
Ventyx falls 19% to $2.39 after Crohn’s disease trial misses endpoint
Premium
The Fly
Ventyx falls 19% to $2.39 after Crohn’s disease trial misses endpoint
8M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100